FDA Inspection 1170628 — AcelRx Pharmaceuticals, Inc.
The FDA completed an inspection of AcelRx Pharmaceuticals, Inc. on May 18, 2022 in Hayward, CA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- May 18, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Hayward, CA (United States)
Additional Details
Risk Evaluation and Mitigation Strategies (REMS)